These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21220126)

  • 1. Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology.
    Dias CR; Jeger S; Osso JA; Müller C; De Pasquale C; Hohn A; Waibel R; Schibli R
    Nucl Med Biol; 2011 Jan; 38(1):19-28. PubMed ID: 21220126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and imaging of small amphiphilic rhenium and (99m)technetium tricarbonyl complexes.
    Boros E; Häfeli UO; Patrick BO; Adam MJ; Orvig C
    Bioconjug Chem; 2009 May; 20(5):1002-9. PubMed ID: 19341277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.
    Pandey U; Kameswaran M; Dev Sarma H; Samuel G
    Appl Radiat Isot; 2014 Apr; 86():52-6. PubMed ID: 24486518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-chain rhenium and technetium glucosamine conjugates.
    Bowen ML; Chen ZF; Roos AM; Misri R; Häfeli U; Adam MJ; Orvig C
    Dalton Trans; 2009 Nov; (42):9228-36. PubMed ID: 20449200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucosamine conjugates bearing N,N,O-donors: potential imaging agents utilizing the [M(CO)3]+ core (M = Re, Tc).
    Bowen ML; Lim NC; Ewart CB; Misri R; Ferreira CL; Häfeli U; Adam MJ; Orvig C
    Dalton Trans; 2009 Nov; (42):9216-27. PubMed ID: 20449199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.
    Stopar TG; Mlinaric-Rascan I; Fettich J; Hojker S; Mather SJ
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):53-9. PubMed ID: 16172899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience.
    Gmeiner Stopar T; Fettich J; Zver S; Mlinaric-Rascan I; Hojker S; Socan A; Peitl PK; Mather S
    Nucl Med Commun; 2008 Dec; 29(12):1059-65. PubMed ID: 18987526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
    Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site.
    Ogawa K; Kawashima H; Kinuya S; Shiba K; Onoguchi M; Kimura H; Hashimoto K; Odani A; Saji H
    Ann Nucl Med; 2009 Dec; 23(10):843-8. PubMed ID: 19921351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
    Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma.
    Nomura S; Ishii K; Kamitsuji Y; Uoshima N; Ishikawa E; Kitayama H; Hayashi K
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):206-12. PubMed ID: 17456632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Centralized radiolabeling of antibodies for radioimmunotherapy.
    Colcher D
    J Nucl Med; 1998 Aug; 39(8 Suppl):11S-13S. PubMed ID: 9708565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S; Emmanouilides C; Bonavida B
    Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and characterization of rhenium and technetium-99m tricarbonyl complexes bearing the 4-[3-bromophenyl]quinazoline moiety as a biomarker for EGFR-TK imaging.
    Bourkoula A; Paravatou-Petsotas M; Papadopoulos A; Santos I; Pietzsch HJ; Livaniou E; Pelecanou M; Papadopoulos M; Pirmettis I
    Eur J Med Chem; 2009 Oct; 44(10):4021-7. PubMed ID: 19487055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. '2+1' Tricarbonyltechnetium(I) and -rhenium(I) mixed-ligand complexes with N-methylpyridine-2-carboxyamide and isocyanide or imidazole ligands-potential precursors of radiopharmaceuticals.
    Fuks L; Gniazdowska E; Kozminski P; Lyczko M; Mieczkowski J; Narbutt J
    Appl Radiat Isot; 2010 Jan; 68(1):90-5. PubMed ID: 19766012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEGylated N-methyl-S-methyl dithiocarbazate as a new reagent for the high-yield preparation of nitrido Tc-99m and Re-188 radiopharmaceuticals.
    Boschi A; Massi A; Uccelli L; Pasquali M; Duatti A
    Nucl Med Biol; 2010 Nov; 37(8):927-34. PubMed ID: 21055623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotensin(8-13) analogue: radiolabeling and biological evaluation using different chelators.
    Teodoro R; Faintuch BL; Núñez EG; Queiróz RG
    Nucl Med Biol; 2011 Jan; 38(1):113-20. PubMed ID: 21220134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.